Aliskiren

Active ingredient description

Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
C09XA02
Aliskiren
C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09X Other agents acting on the renin-angiotensin system → C09XA Renin-inhibitors
Discover more medicines within C09XA02

Medicines

Aliskiren is the active ingredient of these drugs:

Drug
Countries
ALISKIREN

United States

RASILEZ

Austria Canada Cyprus Estonia Hong Kong

RIPRAZO

Ireland

TEKTURNA

South Africa United States

Aliskiren is also found within below combination drugs:

CO RASILEZ , CO TEKTURNA , RASILAMLO , RASILEZ HCT , TEKTURNA HCT

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
RASILEZ Film-coated tablet
Summary of Product Characteristics (SPC)
TEKTURNA Film-coated tablet
Structured Product Labeling (SPL/PLR)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 551.758 g/mol

External identifiers

CAS Substance: 173334-57-1
DrugBank Drug: DB09026
KEGG Drug: D03208
RxNorm Ingredient: 325646
SNOMED-CT Concept: 426725002
Aliskiren (substance)
UNII Identifier: 502FWN4Q32
ALISKIREN
 
Next: Usage >